

IDS date Jan 21, 2005

PTO/SB/08A (08-00)

Please type a plus sign (+) inside this box →

Approved for use through 10/31/2001. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/700,909
(use as many sheets as necessary)				Filing Date	November 4, 2003
				First Named Inventor	John Erbey et al.
				Group Art Unit	1617
				Examiner Name	Shahnam J. Sharareh
Sheet	1	of	2	Attorney Docket Number	CV06093US/4686-050109

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴				
CH	1	WO	99/22728	AI	Arch Development Corporation	May 14, 1999	
CH	2	WO	01/96347	AI	Bristol-Myers Squibb Company	December 20, 2001	

Examiner Signature *Carin Haug* **Date Considered** *2/23/07*

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if

Burden Hour Statement: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450,

Please type a plus sign (+) inside this box → +

Approved for use through 10/31/2001. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A-PTO</p> <h1>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1> <p>(use as many sheets as necessary)</p>			
Complete if Known			
Application Number		10/700,909	
Filing Date		November 4, 2003	
First Named Inventor		John Erbey et al.	
Group Art Unit		1617	
Examiner Name		Shahnam J. Sharreh	
Attorney Docket Number		CV06093/4686-050109	
Sheet	2	of	2

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature	Carrie Murphy	Date Considered	2/23/07
-----------------------	---------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.




Sheet 1 of 16

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: CV6093US01	APPLICATION NO.: 10/700, 909
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: John R. Erbey II, et al.	
				FILING DATE: 11/04/2003	GROUP: 1614

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATIO N	
							YES	NO
CH	AA	BE 884722 A	12/01/80	BELGIUM	C07D	AG1K	X(abs.)	
CH	AB	CA 2253769	11/29/99	CANADA	A61K	31/22		
CH	AC	DE 2046823 A	03/30/72	GERMANY	C07C		X(abs.)	
CH	AD	DE 2521113 A	03/18/76	GERMANY	C07C	87/34	X(abs.)	
CH	AE	EP 0002151 A1,B1	05/30/79	EUROPE	C07C	69/67		
CH	AF	EP 0010299 B1	02/15/84	EUROPE	A61K	45/06		
CH	AG	EP 0179559 A2	04/30/86	EUROPE	C07D	405/06		
CH	AH	EP 0199630 A1	10/29/86	EUROPE	C07D	205/08		
CH	AI	EP 0199630 B1	09/19/90	EUROPE	C07D	205/08		
CH	AJ	EP 0264231 A1	04/20/88	EUROPE	C07D	205/08		
CH	AK	EP 0266896 B1	05/11/88	EUROPE	C07D	471/04		
CH	AL	EP 0274873 B1	07/20/88	EUROPE	C07K	11/00		
CH	AM	EP 0288973 B1	11/02/88	EUROPE	C07D	417/06		
CH	AN	EP 0311366 B1	04/12/89	EUROPE	C07D	471/04		
CH	AO	EP 0333268 A1	09/20/89	EUROPE	C07F	7/18		
CH	AP	EP 0337549 A1	10/18/89	EUROPE	C07D	205/08		
CA	AQ	EP 0337549 B1	10/04/95	EUROPE	C07D	205/08		
CH	AR	EP 0365364 A2	04/25/90	EUROPE	C07D	205/08		
CH	AS	EP 0369686 A1	05/23/90	EUROPE	C07D	463/00		
CH	AT	EP 0375527 A1	06/27/90	EUROPE	C07D	205/08	X(abs.)	
CH	AU	EP 0401705 A3	12/12/90	EUROPE	A61K	31/66		
CH	AV	EP 0415487 A2	03/06/91	EUROPE	C07D	205/08		
CA	AW	EP 0455042 A1	11/06/91	EUROPE	A61K	31/19		
CH	AX	EP 0457514 A1	11/21/91	EUROPE	A61K	45/06		
CH	AY	EP 0457514 B1	08/21/96	EUROPE	A61K	45/06		
CH	AZ	EP 0461548 A3	12/18/91	EUROPE	A61K	31/365		
CH	BA	EP 0462667 A2	12/27/91	EUROPE	C07D	205/08		
CH	BB	EP 0475148 A1	03/18/92	EUROPE	A61K	31/215		
CH	BC	EP 0475755 B1	03/18/92	EUROPE	C07D	403/06		
CH	BD	EP 0481671 A1	04/22/92	EUROPE	C07D	205/08		
CH	BE	EP 0482498 A3	04/29/92	EUROPE	A61K	31/66		
CH	BF	EP 0524595 A1	01/27/93	EUROPE	C07D	205/08		
CH	BG	EP 0720599 B1	07/10/96	EUROPE	C07D	205/08		
CH	BH	EP 0793958 A2	09/10/97	EUROPE	A61K	9/16	X(abs.)	
CH	BI	EP 0814080 A1	12/29/97	EUROPE	C07D	267/14		
CH	BJ	EP 0904781 A2	03/31/99	EUROPE	A61K	31/215		
CH	BK	EP 1048295 A2	11/02/00	EUROPE	A61K	31/216		
CH	BL	FR 1103113	10/31/55	FRANCE				X
CH	BM	FR 2779347	12/10/97	FRANCE	A61	31/215	X(abs.)	
CH	BN	GB 861367	02/22/61	GB	A61K			
CH	BO	GB 902658	08/09/62	GB	C07D			
CH	BP	GB 1415295	11/26/75	GB	C07C	59/26		



Sheet 2 of 16

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE					ATTY. DOCKET NO.: CV06093US01	APPLICATION NO.: 10/700,909
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					APPLICANT: John R. Erbey II, et al.	
(Use several sheets if necessary)					FILING DATE: 11/04/2003	GROUP: 1614

FOREIGN PATENT DOCUMENTS

CH	BQ	GB 2329334 A	03/24/99	GB	A61K	45/00		
CA	BR	JP 028057	10/01/81	JAPAN			X(abs.)	
CA	BS	JP 121479	12/10/86	JAPAN			X(abs.)	
CH	BT	JP 136485	05/26/81	JAPAN			X(abs.)	
CH	BU	JP 180212	03/24/86	JAPAN			X(abs.)	
CA	BV	JP 219681	04/14/87	JAPAN			X(abs.)	
CH	BW	JP 5194209 A	08/03/93	JAPAN	A61K	031/22	X(abs.)	
CH	BX	JP 5239020 A	1993	JAPAN	C07D	205/08	X(abs.)	
CA	BY	JP 4054182 A	1992	JAPAN	C12P	017/16	X(abs.)	
CH	BZ	JP 63017859 A	1988	JAPAN	C07D	205/08	X(abs.)	
CH	CA	JP 4266869 A	1992	JAPAN	C07D	205/08	X(abs.)	
CH	CB	JP 4356195 A	1993	JAPAN			X(abs.)	
CH	CC	JP 4356495	12/10/92	JAPAN			X(abs.)	
CH	CD	JP 5058993 A	1993	JAPAN			X(abs.)	
CH	CE	JP 61280295 A	1987	JAPAN			X(abs.)	
CH	CF	JP 95051558 B2	06/05/95	JAPAN	C07D	205/08	X(abs.)	
CH	CG	JP 91068020	10/25/91	JAPAN	C07D	205/08	X(abs.)	
CA	CH	JP 94047573	06/22/94	JAPAN	C07D	205/08	X(abs.)	
CH	CI	WO 82/01649	05/27/82	PCT	A61K	9/52	X(abs.)	
CH	CJ	WO 87/04429	07/30/87	PCT	C07D	205/08		
CA	CK	WO 88/04656	06/30/88	PCT	C07D	405/04		
CH	CL	WO 88/05296	07/28/88	PCT	A61K	31/365		
CA	CM	WO 91/03249	03/21/91	PCT	A61K	31/785	X(abs.)	
CH	CN	WO 92/13837	08/20/92	PCT	C07D	205/08		
CH	CO	WO 93/02048	02/04/93	PCT	C07D	205/08		
CH	CP	WO 93/07167	04/15/93	PCT	C07J	71/00		
CH	CQ	WO 93/11150	06/10/93	PCT	C07J	71/00		
CH	CR	WO 94/00480	01/06/94	PCT	C07J	71/00		
CH	CS	WO 94/14433	07/07/94	PCT	A61K	31/395		
CH	CT	WO 94/17038	08/04/94	PCT	C07D	205/12		
CH	CU	WO 94/20535	09/15/94	PCT	C07K	13/00		
CH	CV	WO 95/04533	02/16/95	PCT	A61K	31/445		
CH	CW	WO 95/06470	03/09/95	PCT	A61K	31/435		
CA	CX	WO 95/08532	03/30/95	PCT	C07D	205/08		
CH	CY	WO 95/18143	07/6/95	PCT	C07J	71/00		
CH	CZ	WO 95/26334	10/05/95	PCT	C07D	205/08		
CH	DA	WO 95/28919	11/02/95	PCT	A61K	31/19	X(abs.)	
CH	DB	WO 95/35277	12/28/95	PCT	C07D	205/08		
CH	DC	WO 96/00288	01/04/96	PCT	C12N	15/12		
CH	DD	WO 96/09827	04/04/96	PCT	A61K	31/58		
CH	DE	WO 96/16037	05/30/96	PCT	C07D	205/08		

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO.: CV06093US01	APPLICATION NO.: 10/700,909
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>			APPLICANT: John R. Erbey II, et al.		
			FILING DATE: 11/04/2003	GROUP: 1614	

FOREIGN PATENT DOCUMENTS

CH	DF	WO96/19450	06/27/96	PCT	C07D	205/08		
CH	DG	WO 96/19987	07/04/96	PCT	A61K	31/35		
CH	DH	WO 96/40255	12/19/96	PCT	A61K	45/06		
CH	DI	WO 97/16455	05/09/97	PCT	C07H	3/04		
CH	DJ	WO 97/18304	05/22/97	PCT	C12N	15/00		
CH	DK	WO 97/25042	07/17/97	PCT	A61K	31/42		
CH	DL	WO 97/28149	08/07/97	PCT	C07D	307/79		
CH	DM	WO 97/31907	09/04/97	PCT	C07D	263/56		
CH	DN	WO 97/35576	10/02/97	PCT	A61K	31/44		
CH	DO	WO 97/46238	12/11/97	PCT	A61K	31/245		
CH	DP	WO 98/01100	01/15/98	PCT	A61K			
CH	DQ	WO 98/05331	02/12/98	PCT	A61K	31/45		
CH	DR	WO 98/14179	04/09/98	PCT	A61K	9/50		
CH	DS	WO 98/31360	07/23/98	PCT	A61K	31/19		
CH	DT	WO 98/31361	07/23/98	PCT	A61K	31/215	X(abs.)	
CH	DU	WO 98/31366	07/23/98	PCT	A61K	31/445		
CH	DV	WO 98/43081	10/01/98	PCT	G01N	33/50		
CH	DW	WO 98/46215	10/22/98	PCT	A61K	9/20		
CH	DX	WO 98/47518	10/29/98	PCT	A61K	31/715		
CH	DY	WO 98/57652	12/23/98	PCT	A61K	31/785		
CH	DZ	WO 99/04815	04/02/99	PCT	A61K	45/00	X(abs.)	
CH	EA	WO 99/06035	02/11/99	PCT	A61K	31/00		
CH	EB	WO 99/06046	02/11/99	PCT	A61K	31/455		
CH	EC	WO 99/08501	2/25/99	PCT				
CH	ED	WO 99/09967	03/04/99	PCT	A61K	31/00		
CH	EE	WO 99/12534	03/18/99	PCT	A61K	31/17	X(abs.)	
CH	EF	WO 99/11260	03/11/99	PCT	A61K	31/40		
CH	EG	WO 99/15159	04/01/99	PCT	A61K	31/00		
CH	EH	WO 99/15520	04/01/99	PCT	C07D	319/20	X(abs.)	
CH	EI	WO 99/18072	04/15/99	PCT	C07D	205/08		
CH	EJ	WO 99/20275	04/29/99	PCT	A61K	31/47		
CH	EK	WO 99/20614	04/29/99	PCT	C07D	265/36		
CH	EL	WO 99/29300	06/17/99	PCT	A61K	9/107		
CH	EM	WO 99/38498	08/05/99	PCT	A61K	31/00		
CH	EN	WO 99/38845	08/05/99	PCT	C07D	213/65		
CH	EO	WO 99/38850	08/05/99	PCT	C07D	237/32		
CH	EP	WO 99/46232	09/16/99	PCT	C07C	62/34	X(abs.)	
CH	EQ	WO 99/47123	09/23/99	PCT	A61K	9/16		
CH	ER	WO 99/48488	09/30/99	PCT	A61K	31/00		
CH	ES	WO 99/66929	12/29/99	PCT	A61K	31/405		

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO.: CV06093US01	APPLICATION NO.: 10/700,909
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT: John R. Erbey II, et al.	
<i>(Use several sheets if necessary)</i>				FILING DATE: 11/04/2003	GROUP: 1614

FOREIGN PATENT DOCUMENTS

C4	ET	WO 99/66930	12/29/99	PCT	A61K	31/405		
C4	EU	WO 00/04011	01/27/00	PCT	C07D	319/06		
C4	EV	WO 00/07617	02/17/00	PCT	A61K	38/26		
C4	EW	WO 00/16749	03/30/00	PCT	A61K	9/16	X(abs.)	
C4	EX	WO 97/21676	06/19/97	PCT	C07D	205/09		
C4	EY	WO 97/41098	11/06/97	PCT	C07D	205/09		
C4	EZ	WO 00/18395	04/06/00	PCT	A61K	31/215		
C4	FA	WO 00/20623	04/13/00	PCT	C12P	41/00		
C4	FB	WO 00/23415	04/27/00	PCT	C07C	69/734		
C4	FC	WO 00/23416	04/27/00	PCT	C07C	69/734		
C4	FD	WO 00/23425	04/27/00	PCT	C07D	209/80		
C4	FE	WO 00/23445	04/27/00	PCT	C07D	471/12		
C4	FF	WO 00/23451	04/27/00	PCT	C07D	487/14		
C4	FG	WO 00/28981	05/25/00	PCT	A61K	31/00		
C4	FH	WO 00/31548	06/02/00	PCT	G01N	33/68		
C4	FI	WO 00/32189	06/08/00	PCT	A61K	31/415		
C4	FJ	WO 00/34240	06/15/00	PCT	C07D	205/08		
C4	FK	WO 00/37057	06/29/00	PCT	A61K	9/48		
C4	FL	WO 00/37078	06/29/00	PCT	A61K	31/44	X(abs.)	
C4	FM	WO 00/38721	07/06/00	PCT	A61K	45/06		
C4	FN	WO 00/38722	07/06/00	PCT	A61K	45/06		
C4	FO	WO 00/38723	07/06/00	PCT	A61K	45/06		
C4	FP	WO 00/38724	07/06/00	PCT	A61K	45/06		
C4	FQ	WO 00/38725	07/06/00	PCT	A61K	45/06		
C4	FR	WO 00/38726	07/06/00	PCT	A61K	45/06		
C4	FS	WO 00/38727	07/06/00	PCT	A61K	45/06		
C4	FT	WO 00/38728	07/06/00	PCT	A61K	45/06		
C4	FU	WO 00/38729	07/06/00	PCT	A61K	45/06		
C4	FV	WO 00/40247	07/13/00	PCT	C07D	265/26		
C4	FW	WO 00/45817	08/10/00	PCT	A61K	31/505		
C4	FX	WO 00/50392	08/31/00	PCT	C07C	323/52	X(abs.)	
C4	FY	WO 00/53149	09/14/00	PCT	A61K			
C4	FZ	WO 00/53173	09/14/00	PCT	A61K	31/22		
C4	GA	WO 00/53563	09/14/00	PCT	C07C	59/92	X(abs.)	
C4	GB	WO 00/56403	09/28/00	PCT	A61P	9/10		
C4	GC	WO 00/57859	10/05/00	PCT	A61K	9/48		
C4	GD	WO 00/57918	10/05/00	PCT	A61K	47/44		
C4	GE	WO 00/60107	10/12/00	PCT	C12P	17/10		
C4	GF	WO 00/63153	10/26/00	PCT	C07C	69/734		
C4	GG	WO 00/63161	10/26/00	PCT	C07C	237/30		

FORM PTO-1449			U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06093US01	APPLICATION NO.: 10/700,909	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICANT: John R. Erbey II, et al.				
(Use several sheets if necessary)			FILING DATE: 11/04/2003		GROUP: 1614		
FOREIGN PATENT DOCUMENTS							
CH	GH	WO 00/63190	10/26/00	PCT	C07D	265/38	
CH	GI	WO 00/63196	10/26/00	PCT	C07D	277/04	
CH	GJ	WO 00/63209	10/26/00	PCT	C07D	471/04	
CH	GK	WO 00/63703	10/26/00	PCT	G01N	33/92	
CH	GL	WO 00/69412	11/23/00	PCT	A61K	9/127	
CH	GM	WO 00/69445	11/23/00	PCT	A61K	31/785	
CH	GN	WO 00/72825	12/7/00	PCT	A61K	9/14	
CH	GO	WO 00/72829	12/07/00	PCT	A61K	9/48	
CH	GP	WO 00/75103	12/14/00	PCT	C07C	235/60	X(abs.)
CH	GQ	WO 00/76482	12/21/00	PCT	A61K	9/48	
CH	GR	WO 00/76488	12/21/00	PCT	A61K	31/00	
CH	GS	WO 00/78312	12/28/00	PCT	A61K	31/421	
CH	GT	WO 00/78313	12/28/00	PCT	A61K	31/422	
CH	GU	WO 01/00579	01/04/01	PCT	C07D	213/65	
CH	GV	WO 01/00603	01/04/01	PCT	C07D	277/24	
CH	G W	WO 01/08686	02/08/01	PCT	A61K	31/495	
CH	GX	WO 01/12176	02/22/01	PCT	A61K	31/16	
CH	GY	WO 01/12187	02/22/01	PCT	A61K	31/404	
CH	GZ	WO 01/12612	02/22/01	PCT	C07D	257/04	
CH	HA	WO 01/14349	03/01/01	PCT	C07D	277/34	X(abs.)
CH	HB	WO 01/14350	03/01/01	PCT	C07D	277/34	X(abs.)
CH	HC	WO 01/14351	03/01/01	PCT	C07D	277/34	X(abs.)
CH	HD	WO 01/15744	03/08/01	PCT	A61K	49/00	
CH	HE	WO 01/16120	03/08/01	PCT	C07D	263/32	
CH	HF	WO 01/17994	03/15/01	PCT	C07D	413/12	
CH	HG	WO 01/18210	03/15/01	PCT	C12N	15/12	
CH	HH	WO 01/21181	03/29/01	PCT	A61K	31/675	X(abs.)
CH	HI	WO 01/21259	03/29/01	PCT	A61P		
CH	HJ	WO 01/21578	03/29/01	PCT	C07C	235/60	X(abs.)
CH	HK	WO 01/21647	03/29/01	PCT	C07K	14/00	
CH	HL	WO 01/22962	04/05/01	PCT	A61K	31/435	
CH	HM	WO 01/25225	04/12/01	PCT	C07D	317/18	
CH	HN	WO 01/25226	04/12/01	PCT	C07D	327/04	
CH	HO	WO 01/30343	05/03/01	PCT	A61K	31/40	
CH	HP	WO 01/32161	05/10/01	PCT	A61K	31/00	
CH	HQ	WO 01/35970	05/25/01	PCT	A61K	35/76	
CH	HR	WO 01/40192	06/07/01	PCT	C07D	217/26	X(abs.)

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO.: CV06093US01	APPLICATION NO.: 10/700,909
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: John R. Erbey II, et al.	
				FILING DATE: 11/04/2003	GROUP: 1614

FOREIGN PATENT DOCUMENTS

CH	HS	WO 01/45676	06/28/01	PCT	A61K	9/24		
CH	HT	WO 01/49267	07/12/01	PCT	A61K	9/14		
CH	HU	WO 01/64221	09/07/01	PCT	A61K	31/52		
CH	HV	WO 01/76632	10/18/01	PCT	A61K	45/06		
CH	HW	WO 02/50090	06/27/02	PCT	C07H	15/26		
CH	HX	WO 02/058696	08/01/02	PCT	A61K	31/397		
CH	HY	WO 02/058731	08/01/02	PCT	A61K	45/06		
CH	HZ	WO 02/058732	08/01/02	PCT	A61K	45/06		
CH	IA	WO 02/058733	08/01/02	PCT	A61K	45/06		
CH	IB	WO 02/058734	08/01/02	PCT	A61K	45/06		
CH	IC	WO 02/058685	08/01/02	PCT	A61K	31/00		
CH	ID	WO 02/064130	08/22/02	PCT	A61K	31/195		
CH	IE	WO 02/064549	08/22/02	PCT	C07C	275/34		
CH	IF	WO 02/064664	08/22/02	PCT	C08G	77/02		
CH	IG	WO 02/072104	09/19/02	PCT	A61K	31/54		
CH	IH	WO 02/081454	10/17/02	PCT	C07D	239/36		
CH	II	WO 02/26729	04/04/02	PCT	C07D	311/66		
CH	IJ	WO 02/064094	08/22/02	PCT	A61K			
CH	IK	WO 02/50027	06/27/02	PCT				
CH	IL	WO 02/50060	06/27/02	PCT				
CH	IM	WO 02/50068	06/27/02	PCT				
CH	IN	WO 94/26738	11/24/94	PCT				
CH	IO	EP 1 036 563 A1	09/20/00	EPO				
CH	IP	EP 0 753 298 A1	01/15/97	EPO				
CH	IQ	WO 01/34148	05/17/01	PCT				
CH	IR	WO 01/60807	08/23/01	PCT				
CH	IS	WO 02/08188	01/31/02	PCT				
CH	IT	WO 03/039542	05/15/03	PCT				
CH	IU	WO 03/074101	09/12/03	PCT				
CH	IV	WO 03/088962	10/30/03	PCT				
CH	IW	WO 03/018024	03/06/03	PCT	A61K	31/55		
CH	IX	WO 03/018059	03/06/03	PCT	A61K	45/06		

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06093US01	SERIAL NO.: 10/700,909
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT: John R. Erbey II, et al.			
		FILING DATE: 11/04/2003		GROUP: 1614	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
CH	IY	<i>Exhibit A:</i> SCH 58235 Micronized (ezetimibe), Drug Formulation Development Summary			
CH	IZ	<i>Exhibit B:</i> SCH 58235 (ezetimibe), Drug Formulation Development Summary			
CH	JA	<i>Exhibit C:</i> SCH 58235 (ezetimibe), Drug Formulation Development Summary			
CH	JB	<i>Exhibit D:</i> SCH 58235 (ezetimibe), Drug Formulation Development Summary			
CH	JC	<i>Exhibit E:</i> SCH 58235 (ezetimibe), Drug Formulation Development Summary			
CH	JD	<i>Exhibit F:</i> SCH 58235 (ezetimibe), Drug Formulation Development Summary			
CH	JE	<i>Exhibit G:</i> SCH 58235 (ezetimibe), Drug Formulation Development Summary			
CH	JF	<i>Exhibit H:</i> SCH 58235 (ezetimibe), Drug Formulation Development Summary			
CH	JG	<i>Exhibit 1:</i> Master Sheet for the SCH 58235 and Lovastatin Research Study, Schering-Plough Research Institute (Protocol No. C906-411), page 1576-1585			
CH	JH	<i>Exhibit 2:</i> Medical Research Study #1055/97, SCH 58235: Bioavailability of Single Oral Doses of Two Prototype Tablet Formulations and the Reference Capsule Formulation of SCH 58235 in Normal Male Volunteers: A Four Way Crossover Study #C97-221-01, Informed Consent, Peninsular Testing Corporation, page 106-112			
CH	JI	<i>Exhibit 3:</i> Consent Form to Participate in a Research Study, "A Phase II Double Blind Dose Response Investigation of Efficacy and Safety of Four Doses of SCH 58235 Compared to Placebo in Subjects with Primary Hypercholesterolemia," Schering-Plough Research Institute (Protocol No. C98-010), page 1558-1566			
CH	JJ	<i>Exhibit 4:</i> Medical Research Study #1096/99, SCH 58235: Pharmacokinetic Pharmacodynamic Drug Interaction Study with Digoxin in Healthy Volunteers #C98-114, Informed Consent, Peninsular Testing Corporation, page 124-130			
CH	JK	<i>Exhibit 5:</i> Informed Consent, "SCH 58235: Assessment of Multiple-Dose Drug Interaction Between 58235 and Gemfibrozil in Healthy Volunteers," Schering-Plough Research Institute, page 1-8			
CH	JL	Vaccaro, W.D. et al., "Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: enhanced potency by modification of the sugar" <i>Bioorganic & Medicinal Chemistry Ltrs., Oxford, G.B.,</i> 8:313-318 (1998)			
CH	JM	Vaccaro, W.D. et. al., "Carboxy-substituted 2-azetidinones as cholesterol absorption inhibitors", <i>Bioganic & Medicinal Chem. Ltrs. Oxford, G.B.</i> 8:319-322 (1998)			
CH	JN	H. Davis et al., "Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Inhibits the Development of Atherosclerosis in Apo E Knockout Mice", <i>Arterioscler, Thromb. Vasc. Biol</i> 21:2032-2038, (Dec. 2001)			
CH	JO	Simova, E., "Aldol-type addition of hydrocinnamic acid esters to benzylideneaniline", <i>Chemical Abstracts No. 15, 86</i> (April 11, 1997)			
CH	JP	Otto et al., "Stereochemistry of dehydration and halogenation fo αR* and αS* isomeric 3-(α-hydroxybenzyl)-1,4 diphenyl=2 azetidinones, <i>Chemical Abstracts No. 19, 99</i> (Nov. 7, 1983)			
CH	JQ	T. Durst et al, "Metallation of N-Substituted β-Lactams. A Method of the Introduction of 3-substituents into β-Lactams" <i>Canadian Journal of Chemistry, 50:3196-3201</i> (1971)			
CH	JR	Nobuki, O. et al., "Stereoselective syntheses of b-lactam derivatives by ultrasound promoted Reformatskii reaction" <i>Chemical Abstracts No. 106, 17</i> (April 27, 1987)			
CH	JS	M. Hoekman, et al., "Synthesis of Homologues of 4,5-Dihydroxy-and 4-Hydroxy-5-oxohexanoic Acid γ-Lactones", <i>J. Agric. Food Chem., 30:920-024</i> (1982)			

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06093US01	APPLICATION NO.: 10/700,909
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: John R. Erbey II, et al.	
				FILING DATE: 11/04/2003	GROUP: 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
CH	JT	H. Otto <i>et al.</i> "Darstellung und Stereochemie von 3-(α -Hydroxybenzyl)-1,4-diphenyl-2-azetidonen", <i>Liebigs Ann. Chem.</i> 1152-1161 (1983)			
CH	JU	G. George <i>et al.</i> "3-(1'-Hydroxyethyl)-2-Azetidinones From 3-Hydroxybutyrates and N-Arylaldimines" <i>Tetrahedron Letters</i> , 26:3903-3906 (1985)			
CH	JV	Hart <i>et al.</i> "An Enantioselective Approach to Carbapenem Antibodies: Formal Synthesis of (+)-Thienamycin", <i>26 Tetrahedron Letters</i> , 45:5493-5496 (1985)			
CH	JW	Panfil, I. <i>et al.</i> "Synthesis of β -Lactams from α , β -Unsaturated Sugar δ -Lactones" <i>24 Heterocycles</i> 6:1609-1617 (1986)			
CH	JX	D. Roger Illingworth, "An Overview of Lipid-Lowering Drugs" <i>Drugs</i> 36:63:71 (1988)			
CH	JY	Joseph L. Witztum, M.D., "Current Approaches to Drug Therapy for the Hypercholesterolemic Patient" <i>Circulation</i> 80:1101-1114 (1989)			
CH	JZ	B. Ram <i>et al.</i> "Potential Hypolipidemic agents:Part V", 29B Indian J. Chem. 1134-37 (1990)			
CH	KA	Schnitzer-Polokoff, R. <i>et al.</i> , "Effects of Acyl-CoA: Choleseraol O-Acyltransferase Inhibition on Cholesterol Absorption and Plasma Lipoprotein Composition in Hamsters" <i>Comp. Biochem. Physiol.</i> 99A:665-670 (1991)			
CH	KB	Horie, M. <i>et al.</i> , "Hypolipidemic effects of NB-598 in dogs" <i>Atherosclerosis</i> 88:183-192 (1991)			
CH	KC	Baxter, A., "Squalenestatin 1, a Potent Inhibitor of Squalene Synthase, Which Lowers Serum Cholesterol in Vivo", <i>The Journal of Biological Chemistry</i> 267:11705-11708 (1992)			
CH	KD	Summary Factfile, "Anti-Antherosclerotic Agents" <i>Current Drugs Ltd.</i> (1992)			
CH	KE	Harwood H. James, "Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin β -tigogenin cellobioside (CP-88818; tiqueside) 1" <i>Journal of Lipid Research</i> 34:377-395 (1993)			
CH	KF	Salisbury, B. <i>et al.</i> , "Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461" <i>Atherosclerosis</i> 115:45-63 (1995)			
CH	KG	Clader, J. W. <i>et al.</i> , "Substituted (1,2-Diarylethyl)amide Acyl-CoA;Cholesterol Acyltransferase Inhibitors: Effect of Polar Groups in Vitro and in Viro Activity" <i>Journal of Medicinal Chemistry</i> 38:1600-1607 (1995)			
CH	KH	Sybertz, E., "Sch 48461, a novel inhibitor of cholesterol absorption" <i>Atherosclerosis</i> pp. 311-315 (1995)			
CH	KI	Vaccaro, W. <i>et al.</i> , "2-Azetidinone Cholesterol Absorption Inhibitors; Increased Potency by Substitution of the C-4 Phenyl Ring", <i>Bioorg. & Med. Chem.</i> 6:1429-1437 (1998)			
CH	KJ	G. Wu <i>et al.</i> , "A Novel One-Step Diastereo-and enantioselective formation of trans-azetidinones and its application to the total synthesis of cholesterol absorption inhibitors A.C.S. (4/21/99).			
CH	KK	B. Staels, "New Roles for PPARD in Cholesterol Homeostasis", <i>Trends in Pharmacological Sciences</i> , 22:9 p. 444 (Sept. 2001)			
CH	KL	Abbott <i>et al.</i> , "Tricor® Capsules, Micronized", <i>Physicians Desk Reference</i> , January 8, 2001.			
CH	KM	M. Feher <i>et al.</i> , 1991, Lipids and Lipid Disorders, p.1-87 (1991).			

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06093US01	APPLICATION NO.: 10/700,909
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: John R. Erbey II, et al.	
				FILING DATE: 11/04/2003	GROUP: 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
<i>CH</i>	KN	M. Ricote <i>et al.</i> , "New Roles for PPARs in Cholesterol Homeostasis", <i>Trends in Pharmacological Science</i> , Vol. 22, No. 9 44-443 (2001)			
<i>CH</i>	KO	C. Dujovne <i>et al.</i> , "Reduction of LDL Cholesterol in Patients with Primary Hypercholesterolemia by SCH 48461: Results of a multicenter Dose-Ranging Study", <i>J. Clin. Pharm.</i> 41:1 70-78 (Jan. 2001)			
<i>CH</i>	KP	W. Oppolzer <i>et al.</i> , "Asymmetric Diels – Alder Reactions, Facile Preparation and Structure of Sulfonamido – Isobornyl Acrylates", <i>Tetrahedron Letters</i> No. 51, 25:5885-5888 (1984).			
<i>CH</i>	KQ	M. Davidson <i>et al.</i> , "Colesevelam Hydrochloride: a non-absorbed, polymeric cholesterol lowering agent", <i>Expert Opinion Investigating Drugs</i> , 11:2663-71, (Nov. 2000)			
<i>CH</i>	KR	M. Davidson <i>et al.</i> , "Colesevelam hydrochloride (cholestagel): a new, potent bileacid sequestrant associated with a low incidence of gastrointestinal effects", 159 <i>Arch. Intern. Med.</i> 16 1893-900 (Sept. 1999)			
<i>CH</i>	KS	I. Wester, "Cholesterol – Lowering effect of plant sterols", <i>Euro. J. Lipid, Sci. Tech.</i> 37-44 (2000).			
<i>CH</i>	KT	A. Andersson <i>et al.</i> , "Cholesterol –lowering effects of a stanol ester-containing low fat margarine used in conjunction with a strict lipid-lowering diet", 1 <i>European Heart. J. Supplements</i> S80 - S90 (1999)			
<i>CH</i>	KU	H. Gylling <i>et al.</i> , "Reduction of Serum Cholesterol in Postmenopausal Women with Previous Myocardial Infarction and Cholesterol Malabsorption induced by Dietary Sitostanol Ester Margarine, 96 <i>Circulation</i> 12 4226-4231 (Dec. 16, 1997)			
<i>CH</i>	KV	T. Miettinen <i>et al.</i> , "Reduction of Serum Cholesterol with Sitostanol-Ester Margarine in a Mildly Hypercholesterolemic Population", <i>New England Journal of Med.</i> 333 1308-1312 (Nov. 16, 1995)			
<i>CH</i>	KW	T. Bocan <i>et al.</i> , "The ACAT Inhibitor Avasimibe Reduces Macrophages and Matrix Metalloproteinase Expression in Atherosclerotic Lesions of Hypercholesterolemic Rabbits", <i>Arterioscler Thromb Vasc. Biol.</i> 70-79 (Jan. 2000)			
<i>CH</i>	KX	M. Van Heek <i>et al.</i> , "In Vivo Metabolism – Based Discovery of a Potent Cholesterol Absorption Inhibitor, SCH 58235, in the Rat and Rhesus Monkey through the identification of the active metabolites of SCH48461," 283 <i>J. Pharma and Experimental Therapeutics</i> 1 157-163 (1997)			
<i>CH</i>	KY	H. Davis <i>et al.</i> , "The Cholesterol Absorption Inhibitor Ezetimibe Inhibits the Development of Atherosclerosis in apo E knockout (-/-) mice fed low fat and western diets," 151 <i>Atherosclerosis</i> 1:133 (July 2000)			
<i>CH</i>	KZ	L. Nguyen <i>et al.</i> , "Unexpected Failure of Bile Acid Malabsorption to Stimulate Cholesterol Synthesis in Sitosterolemia with Xanthomatosis", 10 <i>Atherosclerosis</i> 2, 289-297 (1990)			
<i>CH</i>	LA	L. Nguyen <i>et al.</i> , "Regulation of Cholesterol Biosynthesis in Sitosterolemia: effects of lovastatin, Cholestyramine, and dietary sterol restriction," 32 <i>J. Lipid Res.</i> 1941-1948 (1991)			
<i>CH</i>	LB	M. Cobb <i>et al.</i> , "Sitosterolemia: Opposing Effects of cholestyramine and Lovastatin on Plasma Sterol Levels in a Homozygous Girl and Her Heterozygous Father," 45 <i>Metabolism</i> 6 673-679 (June 1996)			

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: CV06093US01	APPLICATION NO.: 10/700,909
		APPLICANT: John R. Erbey II, et al.		
		FILING DATE: 11/04/2003	GROUP: 1614	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CH	LC	M. Huettinger et al., "Hypolipidemic Activity of HOE-402 is mediated by Stimulation of the LDL Receptor Pathway", <i>13 Arteriosclerosis and Thrombosis</i> 7 1005-1012 (July 1993).
CH	LD	J. Best et al., "Diabetic Dyslipidaemia", <i>59 Drugs</i> 5 1101-1111 (May 2000)
CH	LE	P. Chong, et al., "Current, New and Future Treatment in Dyslipidaemia and Atherosclerosis", <i>60 Drugs</i> 1 55-93 (July 2000)
CH	LF	M. Brown et al., "A Receptor – Mediated Pathway for Cholesterol Homeostasis", <i>232 Science</i> 34-47 (April 4, 1986)
CH	LG	L. Lipka et al., "Reduction of LDL-Cholesterol and Elevation of HDL-Cholesterol in Subjects with Primary Hypercholesterolemia by SCH 58235: Pooled Analysis of Two Phase II Studies", <i>JACC</i> 257A (Feb. 2000)
CH	LH	Medical Economics, Co., Inc., <i>Physician's Desk Reference</i> , 207-208, 2054 (55 th Ed. 2001)
CH	LI	K. Fassbender et al., "Simvastatin Strongly Reduces Levels of Alzheimer's Disease β -Amyloid Peptides A β 42 and A β 40 in vitro and in vivo", <i>PNAs Early Edition</i> , www.phas.org/cgi/doi/10.1073/phas.081620098 (2001)
CH	LJ	Andrx Announces Results of Alzheimer's Disease Clinical Study", <i>Andrx Corporate Release</i> (April 11, 2001)
CH	LK	Andrx (ADRX): Pos Phase II Results Using Avicor in Alzheimer's: Str Buy; \$130", <i>US Bancorp Piper</i> , April 12, 2001
CH	LL	Statins May Protect Against Alzheimer's Disease; much research needed", <i>Geriatrics</i> February 2001
CH	LM	Dementia and Statins", <i>The Lancet</i> March 17, 2001
CH	LN	Research & Development: Andrx Says Cholesterol Drug May Treat Alzheimers", <i>Reuters</i> April 11, 2001
CH	LO	Cholesterol Drugs Ease Alzheimer's Damage; www.usatoday.com April 10, 2001
CH	LP	Lovastation XL of Use in Alzheimer's? News Edge (May 2, 2001)
CH	LQ	L. Refolo et al., "Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Morse Model", <i>Neurobiology of Disease</i> 321-331 (2000)
CH	LR	D. Kang et al., "Modulation of Amyloid β -protein Clearance and Alzheimer's Disease Susceptibility by the LDL Receptor – Related Protein Pathway", <i>Journal of Clinical Investigation</i> 106:9, 1159-1166 (Nov. 2000)
CH	LS	Y.A. Kesaniewmi, "Intestinal Cholesterol Absorption Efficiency in Man is Related to Apoprotein E Phenotype", <i>J. Clin. Invest.</i> 80(2) 578-81 (Aug. 1987)
CH	LT	J. Busciglio et al., "Generation of β -amyloid in the secretary pathway in neuronal and nonneuronal cells", <i>90 Proc. Nat'l. Acad. Sci, USA</i> , 2092-2096 <i>Neurobiology</i> (March 1993)
CH	LU	L. Farrer et al., "Assessment of Genetic Risk for Alzheimer's Disease Among first Degree Relatives", <i>Annals of Neurology</i> 25:5, 485-493 (May 1989)
CH	LV	A. Goate et al., "Segregation of a Missense Mutation in the Amyloid Precursor Protein Gene with Familial Alzheimer's Disease", <i>349 Nature</i> No. 6311, 704-706 (Feb. 21, 1991)

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06093US01	APPLICATION NO.: 10/700,909
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: John R. Erbey II, et al.		
(Use several sheets if necessary)		FILING DATE: 11/04/2003	GROUP: 1614	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CH	LW	D. Mann <i>et al.</i> , "The Pattern of Acquisition of Plaques and Tangle in the Brains of Patients Under 50 years of Age with Down's Syndrome", <i>89 J. Neuro. Sci.</i> , 169-179 (Feb. 1989)
CH	LX	G. McKhann <i>et al.</i> , "Clinical Diagnosis of Alzheimer's Disease", <i>34 Neurology No. 7</i> , 939-944 (July 1984)
CH	LY	D. Selokoe, "Alzheimer's Disease: Genotypes, Phenotype and Treatments", <i>275 Science</i> , 630-631 (Jan. 31, 1997)
CH	LZ	C. Van Duijn, <i>et al.</i> , "Familial Aggregation of Alzheimer's Disease and Related Disorders: A collaborative Re-Analysis of Case-Control Studies", <i>20 Int'l J. Epidemiology No. 2 (Suppl. 2)</i> , 513-520 (1991)
CH	MA	T Nagahara <i>et al.</i> , "Dibasic (Amidcinoaryl) Propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors", <i>J. Med. Chem</i> 37:1200-1207 (1994)
CH	MB	Mellott <i>et al.</i> , "Acceleration of Recombinant Tissue-Type Plasminogen Activator Induced Reperfusion and Prevention of Reocclusion by Recombinant Antistasin, a selective factor Xa Inhibitor, in a Canine Model of Femoral Arterial Thrombosis", <i>Circulation Research</i> , 70:1152-1160 (1992)
CH	MC	Sitko <i>et al.</i> , "Conjunctive Enhancement of Enzymatic Thrombolysis and Prevention of Thrombotic Reocclusion With the Selective Factor Xa Inhibitor, Tick Anticoagulant Peptide", <i>Circulation</i> , 85:808-815 (1992)
CH	MD	Seymour <i>et al.</i> , 1994, <i>Biochemistry</i> , 33:3949-3959
CH	ME	Markwardt, 1994, <i>Thrombosis and Hemostasis</i> , 72:477-479
CH	MF	Mendall <i>et al.</i> , "C-Reactive Protein and its relation to cardiovascular risk factor: A population based cross sectional study", <i>BMJ</i> ; 312:1061-1065 (April 27, 1996)
CH	MG	Ridker P. <i>et al.</i> , "Prospective Studies of C-Reactive Protein as a risk factor for cardiovascular disease", <i>46 J. Investig. Med.</i> ; 8:391-395 (1998)
CH	MH	Waters, D. <i>et al.</i> , "A Controlled Clinical Trial to Assess the Effect of a Calcium Channel Blocker on the Progression of Coronary Atherosclerosis", <i>Circulation</i> ; 82:1940-1953 (1990)
CH	MI	Fleckenstein, 1985, <i>Cir. Res.</i> Vol 52 (Suppl. 1) 13-16
CH	MJ	Fleckenstein, 1983, "Experimental Facts and Therapeutic Prospects", <i>John Wiley</i> , New York, pp. 286-313
CH	MK	McCall, D., 1985, "Curr. Pract. Cardiol. Vol. 10, 1-11
CH	ML	Remington 1995, "The Science and Practice of Pharmacy; (19 th Ed. 1995) p. 963
CH	MM	M. Chistie <i>et al.</i> , "Early – Onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695", <i>276 J. Biol. Chem.</i> No. 24; 21562-70 (June 15, 2001)
CH	MN	C. Janus <i>et al.</i> , "A β Peptide Immunization Reduces Behavioral impairment and Plaques in a Model of Alzheimer's Disease", <i>408 Nature</i> 21/28; 979-982 (Dec. 2000)
CH	MO	Manual of Laboratory Operations, "Lipid Research Clinics Program Report, Washington, D.C., U.S. Dept. of Health, Education and Welfare Publication; 1:75-628 (1974)
CH	MP	Steiner, PM <i>et al.</i> , "Standardization of Micromethods for Plasma Cholesterol, Triglyceride and HDL-Cholesterol with the Lipid Clinic's Methodology [abstract]", <i>J. Clin. Chem. Clin. Biochem</i> ; 19:850 (1981)

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: CV06093US01	APPLICATION NO.: 10/700,909
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: John R. Erbey II, et al.		
(Use several sheets if necessary)		FILING DATE: 11/04/2003	GROUP: 1614	

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

CH	MQ	Steele WG, et al., "Enzymatic Determinations of Cholesterol in High Density Lipoprotein Fractions Prepared by Precipitation Technique", <i>22 Clin. Chem.</i> ; 1:98-101 (1976)
CH	MR	Salen et al., "Increased Sitosterol Absorption, Decreased Removal and Expanded Body Pools Compensate for Reduced Cholesterol Syntheses in Sitosterolemia with Xanthomatosis", <i>J. Lipid Res.</i> ; 30:1319-1330 (1989)
CH	MS	Lutjohann et al., "Sterol Absorption and Sterol Balance in Phytosterolemia Evaluated by Deuterium-Labeled Sterols: Effect of Sitostanol Treatment", <i>J. Lipid Res.</i> ; 36:8; 1763-1773 (1995)
CH	MT	Zhang et al., "Calpain Inhibitor I Increases B- Amyloid Peptide by Inhibiting the Degradation of the Substrate of γ - Secretase" <i>274 J. Biol. Chem.</i> , 13:8966-8972 (1999)
CH	MU	Zhang et al., "Biochemical Characterization of the γ -Secretase Activity that Produces B-Amyloid Peptides", <i>Biochemistry</i> 40:5049-5055 (2001)
CH	MV	Ida et al., "Analysis of Heterogeneous BA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay", <i>271 J. Biol. Chem.</i> ; 37:22908-22914 (1996)
CH	MW	Lichtlen, P.R. et al., 1990, <i>Lancet</i> ; 335:1109-1113
CH	MX	Bays et al., "Effectiveness and Tolerability of Ezetimibe in Patients with Primary Hypercholesterolemia: Pooled Analysis of Two Phase II Studies", <i>Clinical Therapeutics</i> , 23:1209-1230 (2001)
CH	MY	E. Leitersdorf et al., "Cholesterol absorption inhibition: filling an unmet need in lipid-lowering management", <i>European Heart Journal Suppliment</i> , 3:E17-E23 (June 2001)
CH	MZ	Bauer et al., "Ezetimibe Does not Affect the Pharmacokinetics or Pharmacodynamics of Warfarin", <i>Clinical Pharmacology and Therapeutics</i> , 69:2 p5 (Mar. 6-10, 2001)
CH	NA	Keung et al., "Ezetimibe Does Not Affect the Pharmacokinetics of oral Contraceptives", <i>Clinical Pharmacology and Therapeutics</i> , 69:2 p55 (Mar. 6-10, 2001)
CH	NB	Kosoglou et al., "Pharmacodynamic interaction between fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe", <i>Workshops Lipid Lowering Drugs 72nd EAS Congress</i> , p. 38 (May 21-23, 2001)
CH	NC	T. Kosoglou et al., "Coadministration of Ezetimibe and Fenofibrate Leads to Favorable Effects On Apo CII and LDL Subfractions", <i>Posters 11. Lipid Lowering Drugs/Novel</i> , 72 nd EAS Congress, p. 89 (May 21-23, 2001)
CH	ND	L. Reyderman et al., "Assessment of a Multiple-Dose Drug Interaction Between Ezetimibe and Gemfibrozil", Presented at XIV Int'l Symp. on Drugs Affecting Lipid Metabolism (DALM) N.Y. (Sept. 9-12, 2001)
CH	NE	P. Statkevich et al., "Ezetimibe Does Not Affect the Pharmacokinetics and Pharmacodynamics of Glipizide", <i>Clinical Pharmacology & Therapeutics</i> , 69:67 (March 6-10, 2001)
CH	NF	Knopp et al., "Effect of Ezetimibe on Serum Concentrations of Lipid-Soluble Vitamins", <i>Posters 11. Lipid Lowering Drug/Novel 72nd EAS Congress</i> , p. 90 (May 21-23, 2001)

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06093US01	APPLICATION NO.: 10/700,909
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: John R. Erbey II, et al.	
				FILING DATE: 11/04/2003	GROUP: 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
<i>CH</i>	NG	Kosoglou <i>et al.</i> , "Pharmacodynamic Interaction Between Fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe", <i>Workshops Lipid Lowering Drugs, 72nd EAS Congress</i> , p. 38 (March 6-10, 2001)			
<i>CH</i>	NH	Bays <i>et al.</i> , "Low-Density Lipoprotein Cholesterol Reduction By SCH 58235 (Ezetimibe), A Novel Inhibitor of Intestinal Cholesterol Absorption, in 243 Hypercholesterolemic Subjects: Results of a Dose-Response Study", <i>XII International Symposium on Atherosclerosis, Stockholm, Sweden</i> (June 25-29, 2000)			
<i>CH</i>	NI	Castaner <i>et al.</i> , "Ezetimibe – Hypolipidemic Cholesterol Absorption Inhibitor", <i>Drugs of the Future</i> , 25(7):679-685 (2000)			
<i>CH</i>	NJ	Lipka <i>et al.</i> , "Reduction of LDL-Cholesterol and Elevation of HDL-Cholesterol in Subjects with Primary Hypercholesterolemia by Ezetimibe (SCH 58235): Pooled Analysis of Two Phase II Studies", <i>American College of Cardiology Annual Meeting, Anaheim, CA</i> (March 12-15, 2000)			
<i>CH</i>	NK	Van Heek <i>et al.</i> , "Comparison of the activity and disposition of the novel cholesterol absorption inhibitor , SCH58235, and its glucuronide, SCH60663", <i>British Journal of Pharmacology</i> , 129:1748-1754 (2000)			
<i>CH</i>	NL	Van Heek <i>et al.</i> , 2000, "The potent cholesterol absorption inhibitor, ezetimibe, is glucuronidated in the intestine, localizes to the intestine, and circulates enterohepatically", <i>XII International Symposium of Atherosclerosis, Stockholm Sweden</i> (June 25-29, 2000)			
<i>CH</i>	NM	Iannucci <i>et al.</i> , "Metabolism of SCH 58235 in the Human, Rat and Dog", <i>47th ASMS Conference on Mass Spectrometry and Allied Topics, Dallas, TX</i> (June 13-17, 1999)			
<i>CH</i>	NN	Reiss <i>et al.</i> , "An Enzymatic Synthesis of Glucuronides of Azetidinone-based Cholesterol Absorption Inhibitors", <i>Bioorganic & Medicinal Chemistry</i> , 7:2199-2202 (1999)			
<i>CH</i>	NO	Rosenblum <i>et al.</i> , "Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption", <i>J. Med. Chem.</i> 41:973-980 (1998)			
<i>CH</i>	NP	Vaccaro <i>et al.</i> , "Sugar-Substituted 2-Azetidinone Cholesterol Absorption Inhibitors: Enhanced Potency by Modification of the Sugar", <i>Bioorganic & Medicinal Chemistry Letters</i> , 8:313-318 (1998)			
<i>CH</i>	NQ	Zaks <i>et al.</i> , "Enzymatic Glucuronidation of a Novel Cholesterol Absorption Inhibitor, SCH 58235", <i>Applied Biochemistry and Biotechnology</i> , 73:205-214 (1998)			
<i>CH</i>	NR	W. Insull <i>et al.</i> , "Postmenopausal Hypercholesterolemic Women Derive Additive Benefit from Raloxifene and Simvastatin on Lipid Parameters , <i>World Heart Federation 6th International Symposium on Global Risk of Coronary Heart Disease and Stroke – Abstract Book</i> , p. 35 (June 12-15, 2002)			
<i>CH</i>	NS	L. Simons <i>et al.</i> , 2002, "Ezetimibe added to on-going statin therapy for treatment of primary hypercholesterolemia: Efficacy and safety in patients with Type 2 diabetes mellitus", presented at the 38 th Annual Meeting of the EASD, September 1-5, 2002			
<i>CH</i>	NT	C. Allain <i>et al.</i> , 1974, "Enzymatic Determination of Total Serum Cholesterol", <i>Clinical Chemical</i> , 20:470-475			
<i>CH</i>	NU	R. Mayrhofer <i>et al.</i> , 1980, "Simple-Preparation of 3-Benzylidene-2-azetidinones", <i>Synthesis</i> , 247-248			

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06093US01	APPLICATION NO.: 10/700,909
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: John R. Erbey II, et al.	
				FILING DATE: 11/04/2003	GROUP: 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
CH	NV	Burrier, R.E. et al., 1994, "Demonstration of a Direct Effect on Hepatic Acyl CoA:Cholesterol Acyl Transferase (ACAT) Activity By An Orally Administered Enzyme Inhibitor in the Hamster", <i>Biochemical Pharmacology</i> 47:15451551			
CH	NW	Burrier, R.E. et al., 1994, "The Effect of Acyl CoACholesterol Acyltransferase Inhibitor on the Uptake, Esterification and Secretion of Cholesterol by the Hamster Small Intestine", <i>The Journal of Pharmacology and Experimental Therapeutics</i> 272:156-163			
CH	NX	E.F. Binder et al., "Effects of Hormone Replacement Therapy on Serum Lipids in Elderly Women. A Randomized, Placebo-Controlled Trial", <i>134 Ann. Intern. Med.</i> 9:754-760 (May 1, 2001)			
CH	NY	MR Haymart et al., "Optimal Management of Dyslipidemia in Women and Men", <i>2 J. Gend. Specif. Med.</i> 6:37-42 (Nov. - Dec. 1997)			
CH	NZ	"Framingham Heart Study Analysis Reveals Some Primary Prevention Subgroups Are Being Overlooked", <i>Heartwire</i> (April 12, 2001)			
CH	OA	"Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), "Third Report of the National Cholesterol Education Program (NCEP)", <i>NIH Publication No. 01-3670</i> (May 2001)			
CH	OB	Van Heek et al., "Ezetimibe, A Potent Cholesterol Absorption Inhibitor, Normalizes Combined Dyslipidemia in Obese Hyperinsulinemic Hamsters", <i>50 Diabetes</i> 1330-1335 (June 2001)			
CH	OC	"Additional Statins Show Anti-Inflammatory Effect", <i>103 Circulation</i> 1933-35 (April 17, 2001)			
CH	OD	H. Hauser, et al., "Identification of a Receptor Mediating Absorption of Dietary Cholesterol in the Intestine", <i>Biochemistry</i> 37:17843-17850, 1998			
CH	OE	G. Salen, et al., "Sitosterolemia", <i>Journal of Lipid Research</i> 33:945-955, 1992			
CH	OF	Stedman's Medical Dictionary, 27 th Edition, pg. 1381			
CH	OG	Stuart B. Rosenblum et al., Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(fluorophenyl)-(3S)-hydroxypropyl]- (4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption, <i>J. Med. Chem.</i> 41:973-980 (1998)			
CH	OH	Remington's Pharmaceutical Sciences, 18 th ed. 1990 p. 1319, 1633-1647			
CH	OI	Baker S G et al., Treatment of homozygous familial hypercholesterolemia with probucol, <i>South African Medical Journal</i> (1982)			
CH	OJ	R. Milanese et al., Xantomi E Ipercolesterolemia: Prevalenza, Diagnosi e Terapia, <i>Chron. Derm.</i> 455-61 (1990)			
CH	OK	"Study showed ezetimibe significantly reduced levels of LDL cholesterol or "bad" cholesterol in patients" <i>Schering Press Release</i> 1-3 (2001)			
CH	OL	Kosoglou et al., "Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe" <i>Atherosclerosis</i> (2):3(2001)			
CH	OM	Davis et al., "The Synergistic Hypocholesterolemic Activity of the Potent Cholesterol Absorption Inhibitor, Ezetimibe, in Combination with 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Dogs" <i>Metabolism</i> 50(10):1234-1241(2001)			
CH	ON	Thompson, G.R. et al., "Novel lipid-regulating drugs" <i>Expert Opinion on Investigational Drugs</i> 9(11):2619-2628 (2000), XP008011782			
CH	OO	Kosoglou, T. et al., "Coadministration of ezetimibe and fenofibrate leads to favorable effects on Apo CII and LDL subfractions" <i>Atherosclerosis</i> 2:89 (2001), XP001132089 abstract			
CH	OP	Gilber R. Thompson et al., Novel lipid-regulating drugs, Ashley Publications Ltd. ISSN 1354-3784, 2000, pp. 2619-2628			
CH	OQ	Belamarich P.F. et al., Response to diet and cholestyramine in a patient with sitosterolemia, <i>Pediatrics</i> , ISSN 0031-4005, Dec. 1990			
CH	OR	Salen G. et al., Lethal atherosclerosis associated with abnormal plasma and tissue sterol composition in sitosterolemia with xanthomatosis, <i>Journal of lipid research</i> , ISSN 0022-2275, Sept. 1985			

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06093US01	APPLICATION NO.: 10/700,909
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT: John R. Erbey II, et al.	
(Use several sheets if necessary)				FILING DATE: 11/04/2003	GROUP: 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CH	OS	Sorbera <i>et al.</i> , Netoglitazone, <i>Drugs of the Future</i> , 2002, 27(2): 132-139
CH	OT	Michel Farnier, Nouvelles approches médicamenteuses dans le traitement des dyslipidémies, <i>MT Endocrinologie</i> , 2002, 4:252-259
CH	OU	Berger <i>et al.</i> , Physiological and Therapeutic Roles of Peroxisome Proliferator-Activated Receptors, <i>Diabetes Technology & Therapeutics</i> , 2002, 4:163-174
CH	OV	U.S. Serial No. 10/791,910
CH	OW	U.S. Serial No. 10/792,346
CH	OX	U.S. Serial No. 10/791,979
CH	OY	U.S. Serial No. 10/701,244
CH	OZ	U.S. Serial No. 10/639,900
CH	PA	Cholesterol Drugs May Reverse MS Symptoms, Studies in Mice show statins may treat Multiple Sclerosis – CNN.com/Health, Wednesday, November 6, 2002 posted: 4:30 PM EST (2130 GMT)
CH	PB	D. Grady, Health, Anti-cholesterol Drug Found to Help Paralytic Mice, www.nytimes.com/2002/11/07/health/07DRUG.html
CH	PC	S. Youssef <i>et al.</i> , Atorvastatin, a HMG-CoA Reductase Inhibitor, Promotes a Th2 Bias and Reversal of Paralysis in Chronic Relapsing Autoimmune Encephalomyelitis, <i>Neurology</i> 58 April 2002 (Suppl 3), A384-A385
CH	PD	M. Soili-Hanninen <i>et al.</i> , Semliki Forest Virus Infects Mouse Brain Endothelial Cells and Causes Blood-Brain Barrier Damage, <i>Journal of Virology</i> , Oct. 1994, 6291-6298
CH	PE	Chapter 15 Animal Models for Autoimmune and Inflammatory Disease, Unit 15.1 Experimental Autoimmune Encephalomyelitis in the Mouse, <i>Current Protocols in Immunology</i> , November 6, 2002
CH	PF	J. Pope <i>et al.</i> , Flow Cytometric and Functional Analyses of Central Nervous System-Infiltrating Cells in SJL/J Mice with Theiler's Virus-Induced Demyelinating Disease – Evidence for a CD4+ T Cell-Mediated Pathology, <i>The Journal of Immunology</i> 4050-4058
CH	PG	H. Butzkueven <i>et al.</i> , LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival, 2002 <i>Nature Publishing Group- Nature Medicine</i> , 8:6 613-619 (June 2002)
CH	PH	I. Grewal <i>et al.</i> , CD62L Is Required on Effector Cells for Local Interactions in the CNS to cause Myelin Damage in Experimental Allergic Encephalomyelitis, <i>Immunity</i> , 14:291-302 (March 2001)
CH	PI	E. Tran <i>et al.</i> , Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein -1 α or its CCR5 Receptor, <i>Eur. J. Immunol.</i> , 30:1410-1415 (2000)
CH	PJ	F. Giubilei <i>et al.</i> , Blood cholesterol and MRI activity in first clinical episode suggestive of simple sclerosis, <i>Aeta Neurol Scan</i> , 106:109-112 (2002)
CH	PK	R.O. Weller, <i>Neurology & Applied Neurobiology</i> , Blackwell Scientific Publications, 20:2 April 1994
CH	PL	R. Berkow <i>et al.</i> , <i>The Merck Manual of Medical Information – Home Edition</i> , Pocket Books, Title of Chapter 68 347-350 (1997)
CH	PM	Pelfrey, C., Actrims – Ectrims 2002 (Part II), Baltimore, MD USA, 18-21- September 2002, <i>The Investigational Drugs Database ALERTS</i>
CH	PN	P. Reaney, Cholesterol Drugs may help MS Patients, <i>Yahoo Financial News</i> , Wednesday, November 6, 2002 pm ET
CH	PO	H. Wekerle, Tackling Multiple Sclerosis, <i>Nature</i> , 420:39-84 (2002)
CH	PP	S. Youssef <i>et al.</i> , The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease, <i>Nature</i> , 420:78-84 November 7, 2002

FORM PTO- 1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06093US01	APPLICATION NO.: 10/700,909
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT: John R. Erbey II, et al.	
		FILING DATE: 11/04/2003	GROUP: 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
<input checked="" type="checkbox"/>	PQ	Shestopalov, A.M. et al., Cyclization of Nitriles .XI. Synthesis and reactions of 3-Amino-2-Carboxythieno[2,3-b]-Pyridines, <i>Zhurnal Organicheskoi Khimii</i> , 20:9 1818-1827	
<input checked="" type="checkbox"/>	PR	Shestopalov, A. M. et al., Cyclization of Nitriles .XIX. Synthesis and reactions of the derivatives of 2-oxo-and 2-thioxo-2,5,6,7-Tetrahydro-1H-Pyrindines, <i>Zhurnal Organicheskoi Khimii</i> 22:6 1163-1168	
EXAMINER <i>Carla Hough</i>		DATE CONSIDERED <i>2/23/07</i>	
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			



Sheet 1 of 1

FORM TO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06093	APPLICATION NO.: 10/700,909		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: John R. Erbey II, et al.			
				FILING DATE: 08/07/2003	GROUP:		
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
CH	AL	WO 02/058,734 A	08/01/02	PCT			
CH	AM	WO 02/070,523 A	09/12/02	PCT			
CH	AN	WO 03/082,192 A	10/09/03	PCT			
	AO						
	AP						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
CH	AQ	International Search Report for PCT/US 03/35058 (CV06093) dated April 7, 2003 – 5 Pages					
	AR						
	AS						
	AT						
	AU						
	AV						
EXAMINER <i>Carlie Dugay</i>		DATE CONSIDERED <i>2/28/07</i>					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

Title of Invention	Methods and therapeutic combinations for the treatment of autoimmune disorders
Application Number:	10/700909
Confirmation Number:	7785
First Named Applicant:	John Erbey
Attorney Docket Number:	CV06093
Search string:	(6030990 or 6166049 or 5021461 or 4687777 or 3716583 or 3781328 or 3948973 or 4072705 or 4075000 or 4144232 or 4178695 or 4179515 or 4235896 or 4250191 or 4260743 or 4304718 or 4375475 or 4443372 or 4444784 or 4472309 or 4479900 or 4500456 or 4534786 or 4564609 or 4576748 or 4576749 or 4576753 or 4581170 or 4595532 or 4602003 or 4602005 or 4614614 or 4616047 or 4620867 or 4633017 or 4642903 or 4675399 or 4680391 or 4739101 or 4778883 or 4784734 or 4794108 or 4800079 or 4803266 or 4834846 or 4814354 or 4871752 or 4876365 or 4879301 or 4895726 or 20030153541 or 20020132855 or 20020137689 or 20020128253 or 20020039774 or 20020128252 or 20030013729 or 20030105028 or 20030053981 or 20020183305 or 20020169134 or 20030013699 or 20020151536 or 20020192203 or 20030069221 or 20030119757 or 20020147184 or 20030119796 or 20030119809 or 20030119808 or 20030119428).pn.

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
CA	1	6030990	2000-02-29	Maeda			
CA	2	6166049	2000-12-26	Smith			
CA	3	5021461	1991-06-04	Robinson			
CA	4	4687777	1987-08-18	Meguro			
CA	5	3716583	1973-02-13	Nakamura			



CH	6	3781328	1973-12-25	Witte
CH	7	3948973	1976-04-06	Phillips
CH	8	4072705	1978-02-07	Mieville
CH	9	4075000	1978-02-21	Abdulla
CH	10	4144232	1979-03-13	Koppel
CH	11	4178695	1979-12-18	Erbeia
CH	12	4179515	1979-12-18	Mieville
CH	13	4235896	1980-11-25	Mieville
CH	14	4250191	1981-02-10	Edwards
CH	15	4260743	1981-04-07	Bose
CH	16	4304718	1981-12-08	Kamiya
CH	17	4375475	1983-03-01	Willard
CH	18	4443372	1984-04-17	Luo
CH	19	4444784	1984-04-24	Hoffman
CH	20	4472309	1984-09-18	Kamiya
CH	21	4479900	1984-10-30	Luo
CH	22	4500456	1985-02-19	Spitzer
CH	23	4534786	1985-08-13	Luo
CH	24	4564609	1986-01-14	Tamura
CH	25	4576748	1986-03-18	Greenlee
CH	26	4576749	1986-03-18	Zahler
CH	27	4576753	1986-03-18	Kamiya
CH	28	4581170	1986-04-08	Mueller
CA	29	4595532	1986-06-17	Miller
CH	30	4602003	1986-07-22	Malinow
CH	31	4602005	1986-07-22	Malinow
CH	32	4614614	1986-09-30	Ernest
CH	33	4616047	1986-10-07	Lafon
CH	34	4620867	1986-11-04	Luq
CH	35	4633017	1986-12-30	Mueller
CH	36	4642903	1987-02-17	Davies
CH	37	4675399	1987-06-23	Miller
CH	38	4680391	1987-07-14	Firestone
CH	39	4739101	1988-04-19	Bourgogne
CH	40	4778883	1988-10-18	Yoshioka
CH	41	4784734	1988-11-15	Torii

CH	42	4794108	1988-12-27	Kishimoto
CH	43	4800079	1989-01-24	Boyer
CH	44	4803266	1989-02-07	Kawashima
CH	45	4834846	1989-05-30	Abramson
CH	46	4814354	1989-03-21	Ghebre-Sellassie
CH	47	4871752	1989-10-03	Zermatter
CH	48	4876365	1989-10-24	Kirkup
CH	49	4879301	1989-11-07	Umio
CH	50	4895726	1990-01-23	Curtet

US Published Applications

Note: Applicant is not required to submit a paper copy of cited US Published Applications

init	Cite.No.	Pub. No.	Date	Applicant	Kind	Class	Subclass
CH	1	20030153541	2003-08-14	Dudley			
CH	2	20020132855	2002-09-19	Nelson			
CH	3	20020137689	2002-09-26	Glombik			
CH	4	20020128253	2002-09-12	Glombik			
CH	5	20020039774	2002-04-04	Kramer			
CH	6	20020128252	2002-09-02	Glombik			
CH	7	20030013729	2003-01-16	Iqbal			
CH	8	20030105028	2003-06-05	Schering Corporation			
CH	9	20030053981	2003-03-20	Schering Corporation			
CH	10	20020183305	2002-12-05	Schering Corporation			
CH	11	20020169134	2002-11-14	Schering Corporation			
CH	12	20030013699	2003-01-16	Schering Corporation			
CH	13	20020151536	2002-10-17	Schering Corporation			
CH	14	20020192203	2002-12-19	Schering Corporation			
CH	15	20030069221	2003-04-10	Schering Corporation			
CH	16	20030119757	2003-06-26	Schering Corporation			
CH	17	20020147184	2002-10-10	Schering Corporation			
CH	18	20030119796	2003-06-26	Schering Corporation			
CH	19	20030119809	2003-06-26	Schering Corporation			
CH	20	20030119808	2003-06-26	Schering Corporation			
CH	21	20030119428	2003-06-26	Schering Corporation			

Signature

Examiner Name	Date
<i>Carrie A. Hough</i>	2/23/07



ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

Title of Invention	Methods and therapeutic combinations for the treatment of autoimmune disorders						
Application Number:	10/700909						
Confirmation Number:	7785						
First Named Applicant:	John Erbey						
Attorney Docket Number:	CV06093						
Search string:	(4925672 or 4939248 or 4166907 or 6262042 or 6262047 or 6262098 or 6242605 or 6277584 or 6316029 or RE37721 or H0001286 or 2809194 or 3108097 or 3152173 or 3267104 or 3399192 or 3692895 or 4148923 or 4239763 or 4567195 or 4626549 or 4654362 or 4680289 or 4937267 or 5093365 or 5106833 or 5110730 or 5120713 or 5278176 or 5358852 or 5385885 or 5703188 or 5994554 or 6008237 or 6028109 or 6033656 or 6040147 or 6121319 or 6127424 or 6140354 or 6147090 or 6147109 or 6147250 or 6159997 or 6162805 or 6166049 or 6174665 or 6180138 or 6180625 or 6180660 or 20010028895 or 20020006919).pn.						
US Patent Documents							
Note: Applicant is not required to submit a paper copy of cited US Patent Documents							
init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
CH	1	4925672	1990-05-15	Gremm			
CH	2	4939248	1990-07-03	Yoshioka			
CH	3	4166907	1979-09-04	Krapcho			
CH	4	6262042	2001-07-17	Cook			
CH	5	6262047	2001-07-17	Zhu			
CH	6	6262098	2001-07-17	Huebner			
CH	7	6242605	2001-06-05	Raveendranath			
CH	8	6277584	2001-08-21	Chu			
CH	9	6316029	2001-11-13	Jain			
CH	10	RE37721	2002-05-28	Rosenblum			

CH	11	H0001286	1994-02-01	Eisman
CH	12	2809194	1957-10-08	Novello
CH	13	3108097	1963-10-22	Ugi
CH	14	3152173	1964-10-06	Ehrhart
CH	15	3267104	1966-08-16	Hermans
CH	16	3399192	1968-08-27	Regnier
CH	17	3692895	1972-09-19	Nelson
CH	18	4148923	1979-04-10	Giudicelli
CH	19	4239763	1980-12-16	Milavec
CH	20	4567195	1986-01-28	Schwarz
CH	21	4626549	1986-12-02	Molloy
CH	22	4654362	1987-03-31	Lommen
CH	23	4680289	1987-07-14	Applezweig
CH	24	4937267	1990-06-26	Holloway
CH	25	5093365	1992-03-03	Berge
CH	26	5106833	1992-04-21	Broze
CH	27	5110730	1992-05-05	Edgington
CH	28	5120713	1992-06-09	Mugica
CH	29	5278176	1994-01-11	Lin
CH	30	5358852	1994-10-25	Wu
CH	31	5385885	1995-01-31	Gasic
CH	32	5703188	1997-12-30	Mandeville
CH	33	5994554	1999-11-30	Kliewer
CH	34	6008237	1999-12-28	Sahoo
CH	35	6028109	2000-02-22	Wilson
CH	36	6033656	2000-03-07	Mikami
CH	37	6040147	2000-03-21	Ridker
CH	38	6121319	2000-09-19	Somers
CH	39	6127424	2000-10-03	Martin
CH	40	6140354	2000-10-31	Dax
CH	41	6147090	2000-11-14	DeNinno
CH	42	6147109	2000-11-14	Liao
CH	43	6147250	2000-11-14	Somers
CH	44	6159997	2000-12-12	Tsujita
CH	45	6162805	2000-12-19	Hefti
CH	46	6166049	2000-12-26	Smith

CH	47	6174665	2000-01-16	Dullien
CH	48	6180138	2001-01-30	Engh
CH	49	6180625	2001-01-30	Persson
CH	50	6180660	2001-01-30	Whitney


US Published Applications

Note: Applicant is not required to submit a paper copy of cited US Published Applications

init	Cite.No.	Pub. No.	Date	Applicant	Kind	Class	Subclass
CH	1	20010028895	2002-10-11	Bisgaier			
CH	2	20020006919	2002-01-17	Thosar			

Signature

Examiner Name	Date
<i>Carla M. Angulo</i>	2/23/07



ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

Title of Invention	Methods and therapeutic combinations for the treatment of autoimmune disorders						
Application Number:	10/700909						
Confirmation Number:	7785						
First Named Applicant:	John Erbey						
Attorney Docket Number:	CV06093						
Search string:	(6191117 or 6191159 or 6200998 or 6207697 or 6207699 or 6207822 or 6214831 or 6235706 or 6245743 or 6248781 or 6251852 or 5827536 or 5827541 or 5831091 or 5843984 or 5846966 or 5847008 or 5847115 or 5851553 or 5856473 or 5858409 or 5859051 or 5862999 or 5866163 or 5869098 or 5871781 or 5880148 or 5883109 or 5886171 or 5919672 or 5925333 or 5952003 or 5952321 or 5959123 or 5972389 or 5976570 or 5985936 or 5990102 or 5998441 or 6027747 or 6043257 or 6056975 or 6057342 or 6063764 or 6066653 or 6071899 or 6074670 or 6080767 or 6080778 or 6084082).pn.						
US Patent Documents							
Note: Applicant is not required to submit a paper copy of cited US Patent Documents							
init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
CH	1	6191117	2001-02-20	Kozachuk			
CH	2	6191159	2001-02-20	Pinto			
CH	3	6200998	2001-03-13	Sahoo			
CH	4	6207697	2001-03-27	Han			
CH	5	6207699	2001-03-27	Rothman			
CH	6	6207822	2001-03-27	Thiruvengadam			
CH	7	6214831	2001-04-10	Yokoo			
CH	8	6235706	2001-05-22	Gould			
CH	9	6245743	2001-06-12	Marlowe			
CH	10	6248781	2001-06-19	Jeppesen			
CH	11	6251852	2001-06-26	Gould			

CH	12	5827536	1998-10-27	Laruelle
CH	13	5827541	1998-10-27	Yarwood
CH	14	5831091	1998-11-03	Ohmizu
CH	15	5843984	1998-12-01	Clay
CH	16	5846966	1998-12-08	Rosenblum
CH	17	5847008	1998-12-08	Doebber
CH	18	5847115	1998-12-08	Iwasaki
CH	19	5851553	1998-12-22	Myers
CH	20	5856473	1999-01-05	Shankar
CH	21	5858409	1999-01-12	Karetny
CH	22	5859051	1999-01-12	Adams
CH	23	5862999	1999-01-26	Czekai
CH	24	5866163	1999-02-02	Myers
CH	25	5869098	1999-02-09	Misra
CH	26	5871781	1999-02-16	Myers
CH	27	5880148	1999-03-09	Edgar
CH	28	5883109	1999-03-16	Gregg
CH	29	5886171	1999-03-23	Wu
CH	30	5919672	1999-07-06	Homann
CH	31	5925333	1999-07-20	Krieger
CH	32	5952003	1999-09-14	Guentensberger
CH	33	5952321	1999-09-14	Doherty
CH	34	5959123	1999-09-28	Singh
CH	35	5972389	1999-10-26	Shell
CH	36	5976570	1999-11-02	Greaves
CH	37	5985936	1999-11-16	Novak
CH	38	5990102	1999-11-23	Hickey
CH	39	5998441	1999-12-07	Palkowitz
CH	40	6027747	2000-02-22	Terracol
CH	41	6043257	2000-03-28	Dominguez
CH	42	6056975	2000-05-02	Mitra
CH	43	6057342	2000-05-02	Fevig
CH	44	6063764	2000-05-16	Creasey
CH	45	6066653	2000-05-23	Gregg
CH	46	6071899	2000-06-06	Hickey
CH	47	6074670	2000-06-13	Stamm

CH	48	6080767	2000-06-27	Klein
CH	49	6080778	2000-06-27	Yankner
CH	50	6084082	2000-07-04	Ravikumar

Signature

Examiner Name	Date
<i>Carrie Aungst</i>	2/23/07



ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

Title of Invention	Methods and therapeutic combinations for the treatment of autoimmune disorders						
Application Number:	10/700909						
Confirmation Number:	7785						
First Named Applicant:	John Erbey						
Attorney Docket Number:	CV06093						
Search string:	(6090830 or 6090839 or 6093812 or 6096883 or 6099865 or 6103705 or 6110493 or 6117429 or 6133001 or 6139873 or 6143885 or 5567439 or 5576014 or 5587172 or 5587180 or 5591456 or 5593971 or 5595761 or 5607697 or 5612353 or 5612367 or 5612378 or 5618707 or 5622719 or 5622985 or 5624920 or 5627176 or 5631023 or 5631365 or 5633246 or 5635210 or 5639475 or 5639739 or 5656624 or 5661145 or 5674893 or 5688785 or 5688787 or 5688990 or 5691375 or 5698527 or 5698548 or 5703234 or 5709886 or 5718388 or 5728827 or 5734077 or 5739321 or 5744467 or 5747001).pn.						
US Patent Documents							
Note: Applicant is not required to submit a paper copy of cited US Patent Documents							
Init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
CH	1	6090830	2000-07-18	Myers			
CH	2	6090839	2000-07-18	Adams			
CH	3	6093812	2000-07-25	Thiruvengadam			
CH	4	6096883	2000-08-01	Wu			
CH	5	6099865	2000-08-08	Augello			
CH	6	6103705	2000-08-15	Uzan			
CH	7	6110493	2000-08-29	Guentensberger			
CH	8	6117429	2000-09-12	Bucci			
CH	9	6133001	2000-10-17	Homann			
CH	10	6139873	2000-10-31	Hughes			
CH	11	6143885	2000-11-07	Choi			

CH	12	5567439	1996-10-22	Myers
CH	13	5576014	1996-11-19	Mizumoto
CH	14	5587172	1996-12-24	Cherukuri
CH	15	5587180	1996-12-24	Allen
CH	16	5591456	1997-01-07	Franson
CH	17	5593971	1997-01-14	Tschollar
CH	18	5595761	1997-01-21	Allen
CH	19	5607697	1997-03-04	Alkire
CH	20	5612353	1997-03-18	Ewing
CH	21	5612367	1997-03-18	Timko
CH	22	5612378	1997-03-18	Tianbao
CH	23	5618707	1997-04-08	Homann
CH	24	5622719	1997-04-22	Myers
CH	25	5622985	1997-04-22	Olukotun
CH	26	5624920	1997-04-29	McKittrick
CH	27	5627176	1997-05-06	Kirkup
CH	28	5631023	1997-05-20	Kearney
CH	29	5631365	1997-05-20	Rosenblum
CH	30	5633246	1997-05-27	McKittrick
CH	31	5635210	1997-06-03	Allen
CH	32	5639475	1997-06-17	Bettman
CH	33	5639739	1997-06-17	Dominguez
CH	34	5656624	1997-08-12	Vaccaro
CH	35	5661145	1997-08-26	Davis
CH	36	5674893	1997-10-07	Behounek
CH	37	5688785	1997-11-18	Vaccaro
CH	38	5688787	1997-11-18	Burnett
CH	39	5688990	1997-11-18	Shankar
CH	40	5691375	1997-11-25	Behounek
CH	41	5698527	1997-12-16	Kim
CH	42	5698548	1997-12-16	Dugar
CH	43	5703234	1997-12-30	Iwasaki
CH	44	5709886	1998-01-20	Bettman
CH	45	5718388	1998-02-17	Czekai
CH	46	5728827	1998-03-17	Kannapan
CH	47	5734077	1998-03-31	Regnier

C#	48	5739321	1998-04-14	Wu
C#	49	5744467	1998-04-28	McKittrick
C#	50	5747001	1998-05-05	Wiedmann

Signature

Examiner Name	Date
<i>Carrie Houghn</i>	2/23/07



ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

Title of Invention	Methods and therapeutic combinations for the treatment of autoimmune disorders																																																																																																				
<p>Application Number: 10/700909 Confirmation Number: 7785 First Named Applicant: John Erbey Attorney Docket Number: CV06093 Search string: (5494683 or 5503846 or 5510118 or 5510466 or 5518187 or 5518738 or 5545628 or 5550229 or 5552160 or 5561227 or 5563264).pn.</p>																																																																																																					
<h3>US Patent Documents</h3> <p>Note: Applicant is not required to submit a paper copy of cited US Patent Documents</p> <table border="1"><thead><tr><th>Init</th><th>Cite.No.</th><th>Patent No.</th><th>Date</th><th>Patentee</th><th>Kind</th><th>Class</th><th>Subclass</th></tr></thead><tbody><tr><td>CH</td><td>1</td><td>5494683</td><td>1996-02-27</td><td>Liversidge</td><td></td><td></td><td></td></tr><tr><td>CH</td><td>2</td><td>5503846</td><td>1996-04-02</td><td>Wehling</td><td></td><td></td><td></td></tr><tr><td>CH</td><td>3</td><td>5510118</td><td>1996-04-23</td><td>Bosch</td><td></td><td></td><td></td></tr><tr><td>CH</td><td>4</td><td>5510466</td><td>1996-04-23</td><td>Krieger</td><td></td><td></td><td></td></tr><tr><td>CH</td><td>5</td><td>5518187</td><td>1996-05-21</td><td>Bruno</td><td></td><td></td><td></td></tr><tr><td>CH</td><td>6</td><td>5518738</td><td>1996-05-21</td><td>Eickhoff</td><td></td><td></td><td></td></tr><tr><td>CH</td><td>7</td><td>5545628</td><td>1996-08-13</td><td>Deboeck</td><td></td><td></td><td></td></tr><tr><td>CH</td><td>8</td><td>5550229</td><td>1996-08-27</td><td>Iwasaki</td><td></td><td></td><td></td></tr><tr><td>CH</td><td>9</td><td>5552160</td><td>1996-09-03</td><td>Liversidge</td><td></td><td></td><td></td></tr><tr><td>CH</td><td>10</td><td>5561227</td><td>1996-10-01</td><td>Thiruvengadam</td><td></td><td></td><td></td></tr><tr><td>CH</td><td>11</td><td>5563264</td><td>1996-10-08</td><td>Kume</td><td></td><td></td><td></td></tr></tbody></table>						Init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass	CH	1	5494683	1996-02-27	Liversidge				CH	2	5503846	1996-04-02	Wehling				CH	3	5510118	1996-04-23	Bosch				CH	4	5510466	1996-04-23	Krieger				CH	5	5518187	1996-05-21	Bruno				CH	6	5518738	1996-05-21	Eickhoff				CH	7	5545628	1996-08-13	Deboeck				CH	8	5550229	1996-08-27	Iwasaki				CH	9	5552160	1996-09-03	Liversidge				CH	10	5561227	1996-10-01	Thiruvengadam				CH	11	5563264	1996-10-08	Kume			
Init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass																																																																																														
CH	1	5494683	1996-02-27	Liversidge																																																																																																	
CH	2	5503846	1996-04-02	Wehling																																																																																																	
CH	3	5510118	1996-04-23	Bosch																																																																																																	
CH	4	5510466	1996-04-23	Krieger																																																																																																	
CH	5	5518187	1996-05-21	Bruno																																																																																																	
CH	6	5518738	1996-05-21	Eickhoff																																																																																																	
CH	7	5545628	1996-08-13	Deboeck																																																																																																	
CH	8	5550229	1996-08-27	Iwasaki																																																																																																	
CH	9	5552160	1996-09-03	Liversidge																																																																																																	
CH	10	5561227	1996-10-01	Thiruvengadam																																																																																																	
CH	11	5563264	1996-10-08	Kume																																																																																																	
<p>Signature</p> <table border="1"><tr><td>Examiner Name</td><td>Date</td></tr><tr><td><i>Carrie A. Myrick</i></td><td>2/23/07</td></tr></table>						Examiner Name	Date	<i>Carrie A. Myrick</i>	2/23/07																																																																																												
Examiner Name	Date																																																																																																				
<i>Carrie A. Myrick</i>	2/23/07																																																																																																				



ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18
Stylesheet Version v18.0

Title of Invention	Methods and therapeutic combinations for the treatment of autoimmune disorders						
Application Number:	10/700909						
Confirmation Number:	7785						
First Named Applicant:	John Erbey						
Attorney Docket Number:	CB06093						
Search string:	(5753254 or 5756470 or 5759865 or 5767115 or 5776491 or 5807576 or 5807577 or 5807578 or 5807834 or 5808056 or 5817806 or 4952689 or 4961890 or 4983597 or 4990535 or 5030628 or 5073374 or 5091525 or 5099034 or 5100675 or 5112616 or 5120729 or 5130333 or 5145684 or 5157025 or 5162117 or 5178878 or 5188825 or 5190970 or 5204461 or 5219574 or 5223264 or 5229362 or 5229381 or 5229510 or 5260305 or 5286631 or 5298497 or 5306817 or 5318767 or 5348953 or 5350868 or 5384124 or 5399363 or 5401513 or 5412092 or 5429824 or 5446464 or 5461039 or 5464632).pn.						
US Patent Documents							
Note: Applicant is not required to submit a paper copy of cited US Patent Documents							
init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
CH	1	5753254	1998-05-19	Khan			
CH	2	5756470	1998-05-26	Yumibe			
CH	3	5759865	1998-06-02	Bruns			
CH	4	5767115	1998-06-16	Rosenblum			
CH	5	5776491	1998-07-07	Allen			
CH	6	5807576	1998-09-15	Allen			
CH	7	5807577	1998-09-15	Quali			
CH	8	5807578	1998-09-15	Acosta-Cuello			
CH	9	5807834	1998-09-15	Morehouse			
CH	10	5808056	1998-09-15	Amato			
CH	11	5817806	1998-10-06	Rossi			

CH	12	4952689	1990-08-28	Kawashima
CH	13	4961890	1990-10-09	Boyer
CH	14	4983597	1991-01-08	Yang
CH	15	4990535	1991-02-05	Cho
CH	16	5030628	1991-07-09	Joyeau
CH	17	5073374	1991-12-17	McCarty
CH	18	5091525	1992-02-25	Brennan
CH	19	5099034	1992-03-24	Yoshida
CH	20	5100675	1992-03-31	Cho
CH	21	5112616	1992-05-12	McCarty
CH	22	5120729	1992-06-09	Chabala
CH	23	5130333	1992-07-14	Pan
CH	24	5145684	1992-09-08	Liversidge
CH	25	5157025	1992-10-22	Aberg
CH	26	5162117	1992-11-10	Stupak
CH	27	5178878	1993-01-12	Wehling
CH	28	5188825	1993-02-23	Iles
CH	29	5190970	1993-03-02	Pan
CH	30	5204461	1993-04-20	Murayama
CH	31	5219574	1993-06-15	Wehling
CH	32	5223264	1993-06-29	Wehling
CH	33	5229362	1993-07-20	Kirst
CH	34	5229381	1993-07-20	Doherty
CH	35	5229510	1993-07-20	Knight
CH	36	5260305	1993-11-09	Dennick
CH	37	5286631	1994-02-15	Boeck
CH	38	5298497	1994-03-29	Tschollar
CH	39	5306817	1994-04-26	Thiruvengadam
CH	40	5318767	1994-06-07	Liversidge
CH	41	5348953	1994-09-20	Doherty
CH	42	5350868	1994-09-27	Yoshida
CH	43	5384124	1995-01-24	Courtelie
CH	44	5399363	1995-03-21	Liversidge
CH	45	5401513	1995-03-28	Wehling
CH	46	5412092	1995-05-02	Rey
CH	47	5429824	1995-07-04	June

CH	48	5446464	1995-08-29	Feldle
CH	49	5461039	1995-10-24	Tschollar
CH	50	5464632	1995-11-07	Cousin

Signature

Examiner Name	Date
<i>Carrie Murphy</i>	2/23/07



Sheet 1 of 1

EX-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.:	APPLICATION NO.:
CV06093	10/700,909

APPLICANT:
John R. Erbey II, et al.

FILING DATE:	GROUP:
08/07/2003	

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						YES NO
AM						
AN						
AO						
AP						

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

CH	AQ	T. Kosoglou et al., "CoAdministration of Simvastatin and Ezetimibe Leads to Significant Reduction in LDL-Cholesterol", Proceedings of 3 rd International Congress on Coronary Artery Disease from Prevention to Intervention, Lyon, France p. 271 (2000), XP008027568
	AR	
	AS	
	AT	
	AU	
	AV	

EXAMINER

Carrie Aungel

DATE CONSIDERED

2/23/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.